Soleno Therapeutics Announces Appointment of Veteran Industry Executive Birgitte Volck, M.D., Ph.D., to Board of Directors
12 juin 2019 08h00 HE
|
Soleno Therapeutics
REDWOOD CITY, Calif., June 12, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2019 Financial Results
13 mai 2019 08h00 HE
|
Soleno Therapeutics
REDWOOD CITY, Calif., May 13, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...
Soleno Therapeutics Announces Appointment of Industry Veteran Gwen A. Melincoff to Board of Directors
29 avr. 2019 08h00 HE
|
Soleno Therapeutics
REDWOOD CITY, Calif., April 29, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics to Present at the 2019 H.C. Wainwright Global Life Sciences Conference
03 avr. 2019 08h00 HE
|
Soleno Therapeutics
REDWOOD CITY, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics to Participate in the ROTH Battle of NASH Thrones Spring Investor Conference
25 mars 2019 08h00 HE
|
Soleno Therapeutics
REDWOOD CITY, Calif., March 25, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2018 Financial Results
18 mars 2019 08h00 HE
|
Soleno Therapeutics
REDWOOD CITY, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics to Participate in Two Upcoming Investor Conferences
11 mars 2019 16h05 HE
|
Soleno Therapeutics
REDWOOD CITY, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics Announces $16.5 Million Private Placement
19 déc. 2018 16h01 HE
|
Soleno Therapeutics
Financing Led by Abingworth; Andrew Sinclair, Partner, to Join Soleno’s Board Funding to Support Ongoing Phase III Clinical Program (DESTINY PWS) for DCCR in Prader-Willi Syndrome REDWOOD CITY,...
Soleno Therapeutics Presents Clinical Fat Loss Data on DCCR at the Obesity Society Meeting 2018
15 nov. 2018 08h05 HE
|
Soleno Therapeutics
DCCR treatment resulted in statistically significant decreases in body fat in subjects with Prader-Willi Syndrome REDWOOD CITY, Calif., Nov. 15, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc....
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2018 Financial Results
15 nov. 2018 08h00 HE
|
Soleno Therapeutics
REDWOOD CITY, Calif., Nov. 15, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...